RxDoctor Payments Data

Vy Nguyen, MD

Internal Medicine · Mission Viejo, CANPI 1881671154

Payments from drug & device makers

$11,164in general payments, 2019–2025

Across 628 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$1K
  • Boehringer Ingelheim$1K
  • Amgen$1K
  • Lilly USA, LLC$900
  • AstraZeneca$699
  • plus $5K from 46 others

What the payments were for

  • Consulting fees$250%
  • Food & beverage$11,133100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,164 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$191,203
Medicare patients
327
Services billed
2,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab70$72,098
JardianceEmpagliflozin45$68,025
TrulicityDulaglutide33$61,003
MounjaroTirzepatide46$55,952
EliquisApixaban41$51,729
OzempicSemaglutide42$43,387
SynthroidLevothyroxine Sodium228$26,540
VascepaIcosapent Ethyl15$11,353
TradjentaLinagliptin11$9,369
Icosapent Ethyl20$8,201
Ambien CrZolpidem Tartrate13$8,145
Rosuvastatin Calcium323$6,299
Atorvastatin Calcium562$5,738
Ezetimibe173$4,454
Famotidine201$3,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$900$116,95579 claims
Boehringer IngelheimJardiance, Tradjenta$1,210$77,39456 claims
PfizerEliquis$423$51,72941 claims
Novo NordiskOzempic$593$43,38742 claims
AbbVieSynthroid$1,378$26,540228 claims
AstraZenecaSymbicort$699$2,94913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →